Jason Rhodes Sells 2,160,516 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 2,160,516 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN stock opened at $26.00 on Wednesday. The firm has a market cap of $4.86 billion, a P/E ratio of -7.81 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52 week low of $11.65 and a 52 week high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The firm’s fifty day moving average is $23.18 and its 200 day moving average is $19.61.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts predict that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics in the first quarter worth $26,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Allworth Financial LP acquired a new position in Dyne Therapeutics during the 2nd quarter worth about $62,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics in the 4th quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC increased its stake in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on DYN. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating on the stock. TD Cowen initiated coverage on Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday. Finally, Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.